RU2613421C2 - Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека - Google Patents

Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека Download PDF

Info

Publication number
RU2613421C2
RU2613421C2 RU2013101769A RU2013101769A RU2613421C2 RU 2613421 C2 RU2613421 C2 RU 2613421C2 RU 2013101769 A RU2013101769 A RU 2013101769A RU 2013101769 A RU2013101769 A RU 2013101769A RU 2613421 C2 RU2613421 C2 RU 2613421C2
Authority
RU
Russia
Prior art keywords
seq
variable region
sequence
cmv
light chain
Prior art date
Application number
RU2013101769A
Other languages
English (en)
Russian (ru)
Other versions
RU2013101769A (ru
Inventor
Лоренс М. КАУВАР
Стоут ЭЛЛСВОРТ
Уилльям ЮЗИНДЖЕР
Криста Морин МАККАТЧЕОН
Ин-Пин ЦЗЯН
Фэнь ЧЖАН
Бо ЧЭНЬ
Джизетте СПЕРИНДЕ
Миньха ПАРК
Орит ФУРД
Original Assignee
ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи filed Critical ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи
Publication of RU2013101769A publication Critical patent/RU2013101769A/ru
Application granted granted Critical
Publication of RU2613421C2 publication Critical patent/RU2613421C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2013101769A 2010-06-16 2011-06-16 Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека RU2613421C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35549910P 2010-06-16 2010-06-16
US61/355,499 2010-06-16
PCT/US2011/040761 WO2011159938A2 (en) 2010-06-16 2011-06-16 High affinity human antibodies to human cytomegalovirus (cmv) gb protein

Publications (2)

Publication Number Publication Date
RU2013101769A RU2013101769A (ru) 2014-07-27
RU2613421C2 true RU2613421C2 (ru) 2017-03-16

Family

ID=45348879

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013101769A RU2613421C2 (ru) 2010-06-16 2011-06-16 Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека

Country Status (11)

Country Link
US (3) US9017668B2 (https=)
EP (1) EP2582389B1 (https=)
JP (2) JP6055763B2 (https=)
KR (1) KR101900435B1 (https=)
CN (1) CN103221063B (https=)
AU (1) AU2011268277B2 (https=)
BR (1) BR112012032182A2 (https=)
CA (1) CA2839420C (https=)
IL (1) IL223665B (https=)
RU (1) RU2613421C2 (https=)
WO (1) WO2011159938A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2817217C1 (ru) * 2019-12-04 2024-04-11 Чжухай Триномаб Фармасьютикал Ко., Лтд. Антитело к цитомегаловирусу человека и его применение

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
EP2582389B1 (en) * 2010-06-16 2018-02-21 Trellis Bioscience, LLC High affinity human antibodies to human cytomegalovirus (cmv) gb protein
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
RU2364627C2 (ru) * 2007-11-06 2009-08-20 Власик Татьяна Николаевна Экспрессионный вектор для синтеза белков в клетках млекопитающих
WO2009114560A2 (en) * 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US8003098B2 (en) 2006-02-28 2011-08-23 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-EphA4 antibodies
JP5307708B2 (ja) * 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
CA2657123A1 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspottm applications
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN100575361C (zh) * 2007-04-28 2009-12-30 中国人民解放军第三军医大学野战外科研究所 抗人巨细胞病毒包膜糖蛋白b的人源化单链抗体
US20110171233A1 (en) * 2007-08-22 2011-07-14 Ribovax Biotechnologies S.A. Antibodies Against Human Cytomegalovirus (HCMV)
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
EP2582389B1 (en) * 2010-06-16 2018-02-21 Trellis Bioscience, LLC High affinity human antibodies to human cytomegalovirus (cmv) gb protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
RU2364627C2 (ru) * 2007-11-06 2009-08-20 Власик Татьяна Николаевна Экспрессионный вектор для синтеза белков в клетках млекопитающих
WO2009114560A2 (en) * 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
T. BANKS AND ET. AL., A Major Neutralizing Domain Maps within the Carboxyl-terminal Half of the Cleaved Cytomegalovirus В Glycoprotein, Journal of General Virology, 1989, V.70, pp. 979-985; *
T. BANKS AND ET. AL., A Major Neutralizing Domain Maps within the Carboxyl-terminal Half of the Cleaved Cytomegalovirus В Glycoprotein, Journal of General Virology, 1989, V.70, pp. 979-985;WO 2009114560 A2 от 17.09.2009;US 0007427469 B2 от 23.09.2008;RU 2364627 C2 20.08.2009;RU 2239453 C2 от 10.11.2004. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2817217C1 (ru) * 2019-12-04 2024-04-11 Чжухай Триномаб Фармасьютикал Ко., Лтд. Антитело к цитомегаловирусу человека и его применение

Also Published As

Publication number Publication date
US20170204165A1 (en) 2017-07-20
RU2013101769A (ru) 2014-07-27
WO2011159938A2 (en) 2011-12-22
EP2582389A2 (en) 2013-04-24
WO2011159938A3 (en) 2012-04-19
US20150252099A1 (en) 2015-09-10
JP2013531991A (ja) 2013-08-15
KR101900435B1 (ko) 2018-09-20
CA2839420C (en) 2023-06-13
IL223665B (en) 2020-01-30
AU2011268277A1 (en) 2013-01-31
JP2017038612A (ja) 2017-02-23
BR112012032182A2 (pt) 2016-10-25
US20120020980A1 (en) 2012-01-26
CN103221063B (zh) 2016-08-24
US10030069B2 (en) 2018-07-24
KR20130086036A (ko) 2013-07-30
JP6055763B2 (ja) 2016-12-27
EP2582389B1 (en) 2018-02-21
CN103221063A (zh) 2013-07-24
US9017668B2 (en) 2015-04-28
AU2011268277B2 (en) 2016-10-27
AU2011268277A2 (en) 2013-07-25
EP2582389A4 (en) 2014-01-08
US9688744B2 (en) 2017-06-27
CA2839420A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
RU2613421C2 (ru) Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека
CN113563475B (zh) 一种抗新型冠状病毒的双特异性抗体及其应用
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
CN115710311A (zh) 冠状病毒的抗体或其抗原结合片段
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
KR20100091195A (ko) 항ｒｓｖ ｇ 단백질 항체
CN113444169A (zh) 新型冠状病毒的人源单克隆抗体及其应用
WO2022143816A1 (zh) 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用
CN118369338A (zh) 协同中和新型冠状病毒的人源抗体和抗体组合及其应用
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
CN113980125B (zh) 一种抗sftsv的中和性单克隆抗体及其应用
CN116655785B (zh) 一种抑制寨卡病毒感染的单克隆抗体及其应用
WO1999022008A1 (en) Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
WO2022143815A1 (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN114773461B (zh) 乙型脑炎病毒抗体1d11及其应用
CN118290572B (zh) 抗狂犬病病毒全人源抗体及其组合物与应用
CN114989294B (zh) 一种抗ev71病毒抗体及其制备方法和应用
HK40055435B (en) A bispecific antibody against novel coronavirus and its application
HK40055435A (en) A bispecific antibody against novel coronavirus and its application
CN121159673A (zh) 靶向人乳头瘤病毒的抗体及应用
Guo et al. Construction of immune human library and screening of neutralizing antibodies specific to glycoprotein of severe fever with thrombocytopenia syndrome virus
CN116143910A (zh) 靶向SARS-CoV-2刺突蛋白的纳米抗体及其应用
CN121159672A (zh) 靶向人乳头瘤病毒的抗体及应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180617